

STANDALONE UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER ENDED 31ST MARCH, 2014

(Rs. In lacs except per share data)

PARTICULARS	QTR ENDED			NINE MONTHS ENDED		YEAR ENDED
	31/03/2014	31/12/2013	31/12/2012	31/03/2014	31/12/2012	30/06/2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
a NET SALES / INCOME FROM OPERATIONS (Net of excise duty)	10100.52	13672.05	25012.79	39069.83	81187.41	122992.63
b OTHER OPERATING INCOME	72.05	81.11	65.77	202.58	145.19	317.03
TOTAL INCOME FROM OPERATIONS(NET)(A+B)	10172.57	13753.16	25078.56	39272.41	81332.60	123309.66
2 EXPENSES						
a)Cost of materials consumed	985.36	1526.05	2642.90	3631.32	9416.24	12247.05
b)Purchases of stock-in-trade	4339.08	3583.30	10316.88	10815.21	24418.28	39346.17
c)Changes in inventories of finished goods, work-in-progress and stock-in-trade	-777.90	624.56	-2903.39	1764.44	3593.89	5715.91
d) Employee benefits expense	3038.77	2602.91	3490.60	8231.40	9859.35	15748.79
e)Depreciation and amortisation expense	730.67	743.77	692.91	2216.73	2190.29	3652.09
f)Other expenses	3935.02	2749.20	6088.99	9449.88	16945.55	23344.88
TOTAL EXPENSES	12251.00	11829.79	20328.89	36108.98	66423.60	100054.89
3 PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, FINANCE COSTS AND EXCEPTIONAL ITEMS (1-2)	-2078.43	1923.37	4749.67	3163.43	14909.00	23254.77
4 OTHER INCOME	1157.62	218.42	476.67	1902.57	1654.18	2621.76
5 PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS AND EXCEPTIONAL ITEMS (3-4)	-920.81	2141.79	5226.34	5066.00	16563.18	25876.53
6 Finance costs	6607.41	4280.17	2759.88	14251.04	7477.33	13797.34
7 PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	-7528.22	-2138.38	2466.46	-9185.04	9085.85	12079.19
8 EXCEPTIONAL ITEMS	0.00	0.00	0.00	0.00	508.77	508.77
9 PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)	-7528.22	-2138.38	2466.46	-9185.04	8577.08	11570.42
10 TAX EXPENSES	0.00	0.00	500.00	0.00	1725.00	2196.66
11 NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9-10)	-7528.22	-2138.38	1966.46	-9185.04	6852.08	9373.76
12 EXTRAORDINARY ITEM (NET OF TAX EXP. RS.-Lac)	-	-	-	-	-	-
13 NET PROFIT/(LOSS) FOR THE PERIOD (11-12)	-7528.22	-2138.38	1966.46	-9185.04	6852.08	9373.76
14 SHARE OF PROFIT/(LOSS) OF ASSOCIATES	0.00	0.00	0.00	0.00	0.00	0.00
15 MINORITY INTEREST	0.00	0.00	0.00	0.00	0.00	0.00
16 NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)	-7528.22	-2138.38	1966.46	-9185.04	6852.08	9373.76
17 PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF SHARES Rs. 10/-)	2053.69	2053.69	2053.69	2053.69	2053.69	2053.69
18 RESERVE EXCLUDING REVALUATION RESERVES AS PER BALANCE SHEET OF PREVIOUS ACCOUNTING YEAR	-	-	-	-	-	74845.54
19i EARNINGS PER SHARE (before extraordinary items) (of Rs.10/-each) (not annualised)						
a) Basic	-36.66	-10.41	9.58	-44.72	33.36	45.64
b) Diluted						
19ii EARNINGS PER SHARE (After extraordinary items) (of Rs.10/-each) (not annualised)						
a) Basic	-36.66	-10.41	9.58	-44.72	33.36	45.64
b) Diluted						

A PARTICULARS OF SHAREHOLDING						
1 PUBLIC SHAREHOLDING						
NUMBER OF SHARES	15436656	15196345	12343803	15436656	12343803	13471572
PERCENTAGE OF SHAREHOLDING	75.17	74.00	60.10	75.17	60.10	65.60
2 PROMOTERS & PROMOTER GROUP SHAREHOLDING						
A) PLEDGED/ENCUMBERED						
-NUMBER OF SHARES	4666131	5087560	6729802	4666131	6729802	7024370
-PERCENTAGE OF SHRAES/(AS A % OF THE TOTAL SH HOLDING OF PROMOTER & PROMOTER GROUP)	91.49	95.30	82.14	91.49	82.14	99.42
-PERCENTAGE OF SHRAES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	22.72	24.77	32.77	22.72	32.77	34.20
B) NON - ENCUMBERED						
-NUMBER OF SHARES	434149	251031	1463331	434149	1463331	40094
-PERCENTAGE OF SHRAES/(AS A % OF THE TOTAL SH HOLDING OF PROMOTER & PROMOTER GROUP)	8.51	1.23	17.86	8.51	17.86	0.58
-PERCENTAGE OF SHARES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	2.11	4.70	7.13	2.11	7.13	0.20

PARTICULARS	As on 31/03/2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	0
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	0

Notes:

- 1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 15th May 2014
- 2) The Statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter and nine months ended 31st March 2014 with some audit observations
- 3) The Company operates in pharmaceutical segment only. Hence pursuant to AS-17 on segment reporting, segmental information is not required to be given.
- 4) Provision of tax includes current tax. Deferred tax will be provided at the year end.
- 5) Since the figures pertaining to previous accounting year are based on 15 months accounting year ended on 30th June 2013, the same are not comparable with current accounting year which is of 12 months starting from 1st July 2013 to 30th June 2014.
- 6) Previous year and Quarter figures have been regrouped / rearranged wherever necessary (as per new format under Schedule VI of the Companies Act, 2013)

Place: Mumbai

Date : 15th May, 2014

For Elder Pharmaceuticals Ltd

Alok Jagdish Saxena
Managing Director & CEO

ELDER PHARMACEUTICALS LIMITED

CONSOLIDATED UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER ENDED 31ST MARCH, 2014

(Rs. In lacs except per share data)

PARTICULARS	QTR ENDED			NINE MONTHS ENDED		YEAR ENDED
	31/03/2014	31/12/2013	31/12/2012	31/03/2014	31/12/2012	30/06/2013
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
INCOME FROM OPERATIONS						
a NET SALES / INCOME FROM OPERATIONS (Net of excise duty)	22740.66	38421.64	37402.47	88330.43	113153.86	163853.08
b OTHER OPERATING INCOME	144.84	285.02	66.5	537.86	194.41	317.03
TOTAL INCOME FROM OPERATIONS (NET) (A+B)	22885.5	38706.66	37468.97	88868.29	113348.27	164170.11
2 EXPENSES						
a) Cost of materials consumed	1158.14	1905.74	2813.8	4333.09	9842.05	12583.28
b) Purchases of stock-in-trade	12400.84	18637.95	19139.31	41090.17	44754.89	71182.21
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1424.91	536.18	-3679.73	1234.34	4156.19	-130.19
d) Employee benefits expense	5945.87	7413.37	5665.64	18236.03	15505.57	23914.14
e) Depreciation and amortisation expense	953.39	1106.85	876.96	2982.49	2697.72	4407.57
f) Other expenses	5659.36	6862.15	7751.26	17077	21555.24	29286.65
TOTAL EXPENSES	24692.69	36462.24	32567.24	84953.12	98511.66	141243.64
3 PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, FINANCE COSTS AND EXCEPTIONAL ITEMS (1-2)	-1807.19	2244.42	4901.73	3915.17	14836.61	22926.47
4 OTHER INCOME	1272.58	437.23	511.47	2353.48	1833.54	3269.88
5 PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS AND EXCEPTIONAL ITEMS (3-4)	-534.61	2681.65	5413.2	6268.65	16670.15	26196.35
6 Finance costs	6946.42	4934.71	3097.43	15562.34	8442.75	15482.59
7 PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)	-7481.03	-2253.06	2315.77	-9293.69	8227.4	10713.76
8 EXCEPTIONAL ITEMS	-289.94	48.01	1.25	-241.94	511.3	283.03
9 PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAXES (7-8)	-7191.09	-2301.07	2314.52	-9051.75	7716.1	10430.73
10 TAX EXPENSES	172.13	32.45	447.25	330.55	1684.44	2191.56
11 NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES (9-10)	-7363.22	-2333.52	1867.27	-9382.3	6031.66	8239.17
12 EXTRAORDINARY ITEM (NET OF TAX EXP. RS. -Lacs)	---	---	---	---	---	---
13 NET PROFIT/(LOSS) FOR THE PERIOD (11-12)	-7363.22	-2333.52	1867.27	-9382.3	6031.66	8239.17
14 SHARE OF PROFIT/(LOSS) OF ASSOCIATES	0	0	0	0	0	0
15 MINORITY INTEREST	0	0	0	0	0	0
16 NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)	-7363.22	-2333.52	1867.27	-9382.3	6031.66	8239.17
17 PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF SHARES Rs. 10/-)	2053.69	2053.69	2053.69	2053.69	2053.69	2053.69
18 RESERVE EXCLUDING REVALUATION RESERVES AS PER BALANCE SHEET OF PREVIOUS ACCOUNTING YEAR	---	---	---	---	---	74845.54
19i EARNINGS PER SHARE (before extraordinary items) (of Rs. 10/-each) (not annualised)						
a) Basic	-35.85	-11.36	9.09	-45.69	29.37	40.12
b) Diluted						
19ii EARNINGS PER SHARE (After extraordinary items) (of Rs. 10/-each) (not annualised)						
a) Basic	-35.85	-11.36	9.09	-45.69	29.37	40.12
b) Diluted						


A PARTICULARS OF SHAREHOLDING						
1 PUBLIC SHAREHOLDING:						
NUMBER OF SHARES:	15436656	15198345	12343803	15436656	12343803	13471572
PERCENTAGE OF SHAREHOLDING	75.17	74	60.1	75.17	60.1	65.8
2 PROMOTERS & PROMOTER GROUP SHAREHOLDING						
A) PLEDGED/ENCUMBERED						
-NUMBER OF SHARES	4666131	5087560	6729802	4666131	6729802	7024370
-PERCENTAGE OF SHRAES(AS A % OF THE TOTAL HOLDING OF PROMOTER & PROMOTER GROUP)	91.49	95.3	82.14	91.49	82.14	99.42
-PERCENTAGE OF SHRAES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	22.72	24.77	32.77	22.72	32.77	34.2
B) NON - ENCUMBERED						
-NUMBER OF SHARES	434149	251031	1463331	434149	1463331	40994
-PERCENTAGE OF SHRAES(AS A % OF THE TOTAL HOLDING OF PROMOTER & PROMOTER GROUP)	8.51	1.23	17.86	8.51	17.86	0.58
-PERCENTAGE OF SHARES (AS A % OF TOTAL SHARE CAPITAL OF THE COMPANY)	2.11	4.7	7.13	2.11	7.13	0.2

	As On
PARTICULARS	31.03/2014
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	0
Received during the quarter	1
Disposed of during the quarter	1
Remaining unresolved at the end of the quarter	0

Notes:

- 1) The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 15th May,2014
- 2) The Statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter and nine months ended 31st March,2014 with some audit observations
- 3) The Consolidated results includes the results of the Wholly Owned Subsidiaries of the Company viz. Elder International FZCO, Dubai, Elder Biomed EAD, Bulgaria and Neutrahealth Ltd, UK
- 4) The Company operates in pharmaceutical segment only. Hence pursuant to AS-17 on segment reporting, segmental information is not required to be given.
- 5) Standalone Financial results are available on the Company's website
- 6) Provision of tax includes current tax. Deferred tax will be provided at the year end.
- 7) Since the figures pertaining to previous accounting year are based on 15 months accounting year ended on 30th June 2013, the same are not comparable with current accounting year which is of 12 months starting from 1st July 2013 to 30th June 2014.
- 8) Previous year and Quarter figures have been regrouped / rearranged wherever necessary (as per new format under Schedule VI of the Companies Act, 2013)

For Elder Pharmaceuticals Ltd


Ajay Jagdish Saxena
Managing Director & CEO

Place: Mumbai

Date : 15th May,2014